# A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )

> **NCT07746479** · PHASE3 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 244 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** LZM012

## Key facts

- **NCT ID:** NCT07746479
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-23
- **Primary completion:** 2026-01-26
- **Final completion:** 2026-01-26
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746479, "A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*